Terms: = Prostate cancer AND TNFRSF14, Q92956, 8764, ENSG00000157873, TR2, ATAR, LIGHTR, HVEM, HVEA AND Treatment
3 results:
1. The prognostic utility of the transcription factor SRF in docetaxel-resistant prostate cancer: in-vitro discovery and in-vivo validation.
Lundon DJ; Boland A; Prencipe M; Hurley G; O'Neill A; Kay E; Aherne ST; Doolan P; Madden SF; Clynes M; Morrissey C; Fitzpatrick JM; Watson RW
BMC Cancer; 2017 Mar; 17(1):163. PubMed ID: 28249598
[TBL] [Abstract] [Full Text] [Related]
2. prostate cancer cells increase androgen sensitivity by increase in nuclear androgen receptor and androgen receptor coactivators; a possible mechanism of hormone-resistance of prostate cancer cells.
Fujimoto N; Miyamoto H; Mizokami A; Harada S; Nomura M; Ueta Y; Sasaguri T; Matsumoto T
Cancer Invest; 2007 Feb; 25(1):32-7. PubMed ID: 17364555
[TBL] [Abstract] [Full Text] [Related]
3. Different expression of androgen receptor coactivators in human prostate.
Fujimoto N; Mizokami A; Harada S; Matsumoto T
Urology; 2001 Aug; 58(2):289-94. PubMed ID: 11489729
[TBL] [Abstract] [Full Text] [Related]
